• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538

Research Briefing on 3-methyl-4-sulfamoylbenzoic Acid (CAS: 866997-46-8) in Chemical Biology and Pharmaceutical Applications

3-methyl-4-sulfamoylbenzoic Acid (CAS: 866997-46-8) has emerged as a compound of significant interest in the field of chemical biology and pharmaceutical research. This sulfonamide derivative is being investigated for its potential applications in drug development, particularly as a building block for novel therapeutic agents. Recent studies have highlighted its role in the synthesis of enzyme inhibitors and its interactions with biological targets, making it a valuable candidate for further exploration.

In the context of recent advancements, researchers have focused on the structural and functional properties of 3-methyl-4-sulfamoylbenzoic Acid. Its sulfamoyl group and carboxylic acid moiety provide unique reactivity, enabling its use in the design of small-molecule inhibitors. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a scaffold for carbonic anhydrase inhibitors, showcasing its potential in treating conditions such as glaucoma and epilepsy. The study utilized X-ray crystallography to elucidate the binding interactions of derivatives of 3-methyl-4-sulfamoylbenzoic Acid with the target enzyme.

Another area of active research involves the pharmacokinetic properties of 3-methyl-4-sulfamoylbenzoic Acid. A preclinical study conducted in 2024 evaluated its metabolic stability and bioavailability, revealing favorable absorption characteristics in rodent models. These findings suggest that derivatives of this compound could be optimized for oral administration, addressing a key challenge in drug development. Furthermore, computational modeling has been employed to predict the ADME (Absorption, Distribution, Metabolism, and Excretion) profiles of its analogs, providing insights for future structural modifications.

The synthetic pathways for 3-methyl-4-sulfamoylbenzoic Acid have also been refined in recent years. A 2023 publication in Organic Process Research & Development detailed an efficient, scalable synthesis route with improved yield and purity. This advancement is critical for ensuring the compound's availability for large-scale pharmaceutical applications. Additionally, green chemistry approaches have been explored to minimize environmental impact during production, aligning with the industry's growing emphasis on sustainability.

In conclusion, 3-methyl-4-sulfamoylbenzoic Acid (CAS: 866997-46-8) represents a promising compound with diverse applications in drug discovery and development. Its structural versatility, coupled with recent breakthroughs in its synthesis and biological evaluation, positions it as a valuable tool for researchers. Future studies are expected to explore its potential in targeting additional disease pathways and optimizing its therapeutic efficacy. The ongoing research underscores the importance of this compound in advancing the field of chemical biology and pharmaceutical sciences.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)